½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 25 May 2022 ¨C 20:00 (CEST) ¨C Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, ½ðºÌÓéÀÖ³Ç SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 24 May 2022. 

FMR LLC., notified that, following an acquisition of ½ðºÌÓéÀÖ³Ç shares with voting rights by its affiliates, its shareholding in ½ðºÌÓéÀÖ³Ç SA increased and crossed the 5% threshold on 18 May 2022.

On 18 May 2022, FMR LLC. (taking into account the holding of its affiliates) owned 9 763 725 ½ðºÌÓéÀÖ³Ç shares with voting rights, representing 5.02% of the total number of shares issued by the company (194 505 658), versus 4.99% (9 714 254 ½ðºÌÓéÀÖ³Ç shares) in the previous notification dated 23 May 2022.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights. 
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 18 May 2022. 
• Threshold crossed (in %): 5%.
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:

• Additional information: The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

3.  Further information 

This press release and the detailed transparency notification are available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

An updated overview of the ½ðºÌÓéÀÖ³Ç SA/NV large shareholdings will be available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news